HomeInsightsResults

Indoco Remedies Ltd Quarterly Result

Indoco Remedies Ltd Quarterly Result

stocks purchased

₹ 0.1 Cr

Volume Transacted

(Nov 29, 2024)

stocks purchased

2.0 K

Stocks Traded

(Nov 29, 2024)

Last Updated on: Nov 30, 2024

Image

Indoco Remedies Ltd

NSE: INDOCO

Net Profit

₹ -10.01

Last updated on: Nov 30, 2024

Key Highlights

  • The revenue of Indoco Remedies Ltd for the Sep '24 is ₹ 434.22 crore as compare to the Jun '24 revenue of ₹ 432.52 crore. This represent the growth of 0.39304823%.
  • The ebitda of Indoco Remedies Ltd for the Sep '24 is ₹ 41.81 crore as compare to the Jun '24 ebitda of ₹ 48.8 crore. This represent the decline of -14.323766%.
  • The net profit of Indoco Remedies Ltd for the Sep '24 is ₹ -10.01 crore as compare to the Jun '24 net profit of ₹ 1.82 crore. This represent the decline of -650%.

Results Analysis

Market Price of Indoco Remedies Ltd

1M

1Y

3Y

5Y

Monitoring Indoco Remedies Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
29 Nov 2024324.85
28 Nov 2024315.2
27 Nov 2024305.35
26 Nov 2024315.95
25 Nov 2024322.05
22 Nov 2024320
21 Nov 2024299.85
19 Nov 2024304.3
18 Nov 2024307.4
14 Nov 2024309.15

Historical Revenue of Indoco Remedies Ltd

No data available

* All values are in crore

Historical EBITDA of Indoco Remedies Ltd

No data available

* All values are in crore

Historical Net Profit of Indoco Remedies Ltd

No data available

* All values are in crore

Indoco Remedies Ltd News Hub

News

Indoco Remedies slides as Q2 PAT tumbles 61% YoY to Rs 13 cr

Revenue from operations decreased by 15.18% year on year (YoY) to Rs 394.58 crore in the q...

Read more

24 Oct 202415:21

News

Indoco Remedies to convene board meeting

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 24 October...

Read more

15 Oct 202410:33

News

Indoco Remedies' Goa plant classified as OAI by US FDA

In a regulatory filing made after market hours on Friday, the pharmaceutical company infor...

Read more

14 Oct 202409:28

News

Indoco Remedies update on USFDA inspection of its facilities in Goa

Indoco Remedies has received regulatory status from U.S. Food and Drug Administration (USF...

Read more

11 Oct 202419:10

News

Indoco Remedies receives USFDA approval for Cetirizine Hydrochloride Tablets

Indoco Remedies (Indoco) announced the receipt of final approval from the USFDA for Abbrev...

Read more

04 Oct 202414:26

News

Indoco Remedies AGM scheduled

Indoco Remedies announced that the Annual General Meeting (AGM) of the company will be hel...

Read more

31 Aug 202416:28

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQ's For Indoco Remedies Ltd Quarterly Result

What is the EPS of Indoco Remedies Ltd stock?

The Earnings Per Share (EPS) of Indoco Remedies Ltd is 2.66. An EPS is the amount of net income attributed to each share of a common stock.

How is Indoco Remedies Ltd EPS calculated?

The EPS of Indoco Remedies Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Indoco Remedies Ltd report its EPS?

Indoco Remedies Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Indoco Remedies Ltd EPS?

Factors that influence the EPS of Indoco Remedies Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Indoco Remedies Ltd EPS growth indicate future performance?

Yes, consistent growth in Indoco Remedies Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading starting at just

Rs. 249*